Calcium channel current in cultured rat mesangial cells. 1993

M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
Department of Pharmacology, Fukui Medical School, Japan.

The presence of voltage-dependent calcium channels has been suggested in mesangial cells by using calcium-sensitive fluorescent probes. However, direct electrophysiological evidence for voltage-dependent calcium channels has not yet been presented. In this study voltage-dependent calcium channels were studied in cultured rat mesangial cells. Whole-cell patch-clamp experiments were done with 50 mM Ba2+ as a charge carrier. Step depolarizing pulses from a holding potential of -50 mV produced an inward barium current at potentials more positive than -10 mV, and a peak current (10-45 pA) was obtained at a membrane potential of approximately +30 mV. The inward current was augmented by 100 nM Bay K 8644, attenuated by 1 microM nifedipine, and abolished by 50 microM Cd2+. These results indicate that the inward current is a barium current flowing through L-type calcium channels. This may be the first study that demonstrates the presence of L-type calcium channels in mesangial cells.

UI MeSH Term Description Entries
D008297 Male Males
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005920 Glomerular Mesangium The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX. Mesangium, Glomerular,Mesangial Extracellular Matrix,Extracellular Matrices, Mesangial,Extracellular Matrix, Mesangial,Glomerular Mesangiums,Matrices, Mesangial Extracellular,Matrix, Mesangial Extracellular,Mesangial Extracellular Matrices,Mesangiums, Glomerular
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001498 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool. BK-8644,Bay R5417,Bay-K-8644,Bay-K-8644, (+)-Isomer,Bay-K-8644, (+-)-Isomer,Bay-K-8644, (-)-Isomer,Bay-K8644,Bay-R-5417,BK 8644,BK8644,Bay K 8644,Bay K8644,Bay R 5417,BayK8644,BayR5417,R5417, Bay
D015220 Calcium Channels Voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorized as L-, T-, N-, P-, Q-, and R-types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins. The L- and T-types are present throughout the cardiovascular and central nervous systems and the N-, P-, Q-, & R-types are located in neuronal tissue. Ion Channels, Calcium,Receptors, Calcium Channel Blocker,Voltage-Dependent Calcium Channel,Calcium Channel,Calcium Channel Antagonist Receptor,Calcium Channel Antagonist Receptors,Calcium Channel Blocker Receptor,Calcium Channel Blocker Receptors,Ion Channel, Calcium,Receptors, Calcium Channel Antagonist,VDCC,Voltage-Dependent Calcium Channels,Calcium Channel, Voltage-Dependent,Calcium Channels, Voltage-Dependent,Calcium Ion Channel,Calcium Ion Channels,Channel, Voltage-Dependent Calcium,Channels, Voltage-Dependent Calcium,Voltage Dependent Calcium Channel,Voltage Dependent Calcium Channels
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
November 1991, The American journal of physiology,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
November 1993, The Journal of pharmacology and experimental therapeutics,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
September 1994, Biochemical and biophysical research communications,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
March 1993, Kidney international,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
July 1997, The American journal of physiology,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
November 1985, FEBS letters,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
November 2000, The Journal of membrane biology,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
October 1989, British journal of pharmacology,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
July 1994, Kidney international,
M Nishio, and H Tsukahara, and M Hiraoka, and M Sudo, and S Kigoshi, and I Muramatsu
September 1984, Proceedings of the Royal Society of London. Series B, Biological sciences,
Copied contents to your clipboard!